Stock comparison
GSK
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GSK
GSK
Market cap
$103.33B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GSK | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 77B | LMAT |
| Benjamin Graham | 62C | 89A | LMAT |
| Philip Fisher | 66B | 81C | LMAT |
| Peter Lynch | 47D | 67B | LMAT |
| Joel Greenblatt | 35D | 56D | LMAT |
| Charlie Munger | 65C | 68D | LMAT |
| Terry Smith | 63C | 69D | LMAT |
Side-by-side metrics
| Metric | GSK | LMAT |
|---|---|---|
| Market cap | $103.33B | $2.23B |
| P/E (TTM) | 12.9x | 37.1x |
| EV/EBIT | 10.8x | 36.6x |
| ROIC (TTM) | 13.76% | 9.43% |
| Gross margin | 72.74% | 72.39% |
| Net margin | 17.78% | 24.35% |
| Revenue CAGR 5y | 7.24% | 12.75% |
| EPS CAGR 5y | 19.78% | 19.04% |
| Debt / Equity | 1.1x | 0.5x |
| Dividend yield | 3.6% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GSK leads on
- Market cap$103.33Bvs $2.23B+98%
- Dividend yield3.6%vs 0.84%+77%
- EV/EBIT10.8xvs 36.6x+71%
- P/E (TTM)12.9xvs 37.1x+65%
LMAT leads on
- Debt / Equity0.5xvs 1.1x+56%
- Revenue CAGR 5y12.75%vs 7.24%+43%
- Net margin24.35%vs 17.78%+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.